Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide/Formoterol Inhalation Powder (II) vs Symbicort Turbuhaler in Adult Asthma
CTR20234330Phase 3Completed
- Sponsor
- Shanghai Xinhuanghe Pharmaceutical
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of budesonide + formoterol in asthma, chronic obstructive pulmonary disease (COPD), sponsored by Shanghai Xinhuanghe Pharmaceutical. Started Jan 2024; status: completed.
02
Drugs
budesonide + formoterol
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20234330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20234330.